Your browser is no longer supported. Please, upgrade your browser.
AIMT Aimmune Therapeutics, Inc. daily Stock Chart
AIMT [NASD]
Aimmune Therapeutics, Inc.
Index- P/E- EPS (ttm)-3.97 Insider Own0.50% Shs Outstand67.87M Perf Week-4.43%
Market Cap906.74M Forward P/E- EPS next Y-2.35 Insider Trans32.00% Shs Float50.20M Perf Month-40.25%
Income-248.50M PEG- EPS next Q-1.18 Inst Own84.10% Short Float28.31% Perf Quarter-61.93%
Sales- P/S- EPS this Y-8.20% Inst Trans-0.14% Short Ratio7.70 Perf Half Y-43.22%
Book/sh1.64 P/B8.15 EPS next Y40.70% ROA-90.70% Target Price43.20 Perf Year-42.19%
Cash/sh2.11 P/C6.32 EPS next 5Y34.60% ROE-138.40% 52W Range10.09 - 37.00 Perf YTD-60.08%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-63.89% Beta0.91
Dividend %- Quick Ratio3.10 Sales past 5Y- Gross Margin- 52W Low32.41% ATR1.59
Employees215 Current Ratio3.10 Sales Q/Q- Oper. Margin- RSI (14)32.07 Volatility7.93% 12.41%
OptionableYes Debt/Eq0.39 EPS Q/Q-11.00% Profit Margin- Rel Volume0.87 Prev Close13.94
ShortableYes LT Debt/Eq0.39 EarningsFeb 27 AMC Payout- Avg Volume1.85M Price13.36
Recom2.30 SMA20-7.71% SMA50-41.25% SMA200-45.11% Volume1,610,600 Change-4.16%
Mar-18-20Downgrade JMP Securities Mkt Outperform → Mkt Perform
Feb-28-20Reiterated H.C. Wainwright Neutral $33 → $30
Feb-03-20Reiterated Wedbush Outperform $79 → $81
Dec-19-19Initiated H.C. Wainwright Neutral $33
Dec-13-19Downgrade Credit Suisse Outperform → Neutral $30
Jul-12-19Resumed ROTH Capital Buy $45
May-21-19Resumed Credit Suisse Outperform $36 → $30
Dec-13-18Initiated Goldman Neutral $32
May-18-18Resumed Piper Jaffray Overweight
Feb-07-18Initiated RBC Capital Mkts Outperform $55
Dec-21-17Initiated Robert W. Baird Outperform $64
Nov-20-17Initiated ROTH Capital Buy
Sep-26-16Initiated JMP Securities Mkt Outperform
Mar-01-16Initiated Wedbush Outperform $42
Nov-17-15Reiterated Piper Jaffray Overweight $35 → $38
Aug-31-15Initiated Piper Jaffray Overweight $35
Aug-31-15Initiated Credit Suisse Outperform $44
Aug-31-15Initiated BofA/Merrill Buy $36
Mar-22-20 08:06AM  Independent Director Patrick Enright Just Bought Shares In Aimmune Therapeutics, Inc. (NASDAQ:AIMT) Simply Wall St.
Mar-21-20 09:15AM  Bad Week Gets Worse as Morning Rally Falters Zacks
Mar-17-20 10:40PM  Peanut allergy patients ready for Peninsula company's new drug as COVID-19 slows launch American City Business Journals
Mar-16-20 01:12PM  Aimmune sees slowdown in launch of peanut allergy therapy due to coronavirus Reuters -23.36%
08:00AM  Aimmune Announces First U.S. Patients Are Being Treated with Newly-Approved PALFORZIA, the First Treatment for Peanut Allergy Business Wire
Mar-13-20 05:00PM  Aimmune Announces New PALFORZIA Data Suggesting Increased Desensitization, Improved Tolerability and Continued Immunomodulation After 18 and 24 Months of Treatment Business Wire
Mar-11-20 06:25PM  Edited Transcript of AIMT earnings conference call or presentation 27-Feb-20 9:30pm GMT Thomson Reuters StreetEvents -9.29%
Feb-27-20 04:05PM  Aimmune Therapeutics Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Recent Operational Highlights Business Wire -7.53%
07:35AM  The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy Benzinga
Feb-26-20 08:00AM  Aimmune Therapeutics to Present at Upcoming Investor Conferences Business Wire
Feb-25-20 08:00AM  Aimmune to Present New Clinical Data at AAAAI Annual Meeting Business Wire
Feb-21-20 09:01AM  Is the Options Market Predicting a Spike in Aimmune (AIMT) Stock? Zacks
Feb-20-20 05:43PM  Startup gobbles up $60M from high-profile investors to target food allergies American City Business Journals
08:30AM  Aimmune Therapeutics to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2019 Financial Results and Recent Operational Highlights Business Wire
Feb-19-20 10:13AM  What's in Store for Aimmune (AIMT) This Earnings Season? Zacks
Feb-13-20 06:45AM  Bingeing Alone Isnt Enough for Nestle Bloomberg
Feb-12-20 05:50PM  Aimmune Therapeutics (AIMT) Stock Sinks As Market Gains: What You Should Know Zacks
Feb-06-20 10:50AM  Aimmune Analyst Says Palforzia Launch Funding Secured With Nestle's $200M Investment Benzinga
Feb-05-20 02:19PM  Aimmunes Prospects Shine After the FDA Approves Its Allergy Drug InvestorPlace
12:07PM  Nestle invests $200 million more in Aimmune after peanut allergy drug approval Reuters
11:52AM  Steven Cohen Renews His Interest in Verastem GuruFocus.com
11:15AM  Biotech Stock Roundup: Earnings Updates From VRTX, AMGN, GILD; AIMT Gains FDA Nod Zacks
10:28AM  After peanut allergy drug approval, Peninsula biotech munches sweet $200M deal American City Business Journals
10:10AM  Allergy-Medication Firm Aimmune Gets Added $200 Million Nestlé Investment TheStreet.com
08:58AM  Aimmune's stock is up on Nestlé investment MarketWatch
08:06AM  Aimmune Therapeutics Announces Additional $200 Million Equity Investment by Nestlé Health Science Business Wire
08:01AM  Aimmune Licenses Exclusive Worldwide Rights to Xencors XmAb®7195 for the Development of Next-Generation Food Allergy Treatments Business Wire
Feb-04-20 10:22AM  Analysts Forecast Huge Upsides for Aimmune, Biohaven GuruFocus.com -11.03%
Feb-03-20 04:16PM  Aimmune Stock Flies On First-Of-Its-Kind Peanut Allergy Approval Investor's Business Daily +6.31%
11:47AM  Aimmune Analysts Bullish On Strong Uptake Of Peanut Allergy Drug Palforzia Benzinga
11:11AM  Aimmune's Palforzia Wins FDA Approval for Peanut Allergy Zacks
Feb-01-20 03:53PM  Aimmune's 'First-Of-Its-Kind' Peanut Allergy Drug Receives FDA Approval Benzinga
Jan-31-20 06:13PM  FDA Approves First Drug for Peanut Allergy Bloomberg
06:04PM  Peanut allergy drug from Peninsula company approved by FDA American City Business Journals
05:20PM  Aimmune Therapeutics stock rallies after FDA approves peanut-allergy drug MarketWatch
05:04PM  FDA Approves Aimmunes PALFORZIA as First Treatment for Peanut Allergy Business Wire
Jan-20-20 02:18PM  7 Blockbuster Drugs Expected To Be Launched In 2020 Benzinga
Jan-10-20 09:11AM  Is the Options Market Predicting a Spike in Aimmune Therapeutics (AIMT) Stock? Zacks
Jan-09-20 05:56PM  Delayed by last year's gov't shutdown, Peninsula biotech now in line for first food allergy drug American City Business Journals -8.40%
Jan-06-20 08:30AM  Aimmune Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-30-19 09:24AM  3 Healthcare Stocks With Huge FDA Decisions in January TipRanks
Dec-23-19 10:49AM  Best Stocks for 2020: Aimmunes Allergy Solutions Position It for Huge Success InvestorPlace
Dec-08-19 06:24PM  Do Hedge Funds Love Aimmune Therapeutics Inc (AIMT) ? Insider Monkey
Nov-15-19 04:05PM  Aimmune to Participate in Three Upcoming Investor Conferences Business Wire
Nov-14-19 10:03PM  Edited Transcript of AIMT earnings conference call or presentation 6-Nov-19 9:30pm GMT Thomson Reuters StreetEvents
Nov-08-19 11:00AM  Quality of Life Outcomes from Two New Surveys Highlight Emotional Impact of Peanut Allergy and Need for New Treatments Business Wire
11:00AM  New Data Presented at ACAAI 2019 Show Importance of Clinical History in Identifying AR101-Eligibile Patients for PALISADE Study without a Food Challenge Business Wire
07:00AM  New Real-World Data Unveiled at ACAAI Indicates Comparable Clinical Practice Logistics to Implement Oral Immunotherapy and Environmental Allergy Shots Business Wire
07:00AM  AR101 Demonstrates Consistent Efficacy and Safety in New Analysis at ACAAI Comparing PALISADE and ARTEMIS Phase 3 Clinical Data Business Wire
Nov-06-19 04:05PM  Aimmune Therapeutics Announces Third Quarter 2019 Financial Results and Provides Operational Highlights Business Wire
08:21AM  The Daily Biotech Pulse: Sesen Rallies On Positive FDA Meeting, Supernus Flunks Late-Stage ADHD Trial, GW Pharma Earnings Benzinga
Nov-04-19 04:05PM  Aimmune to Participate in the Credit Suisse 28th Annual Healthcare Conference Business Wire
Oct-31-19 07:00AM  Aimmune to Present New Data on Safety and Efficacy of AR101, Clinical Practice Implementation of Oral Immunotherapy, Quality of Life and Other Related Studies at ACAAI 2019 Business Wire
Oct-30-19 07:00AM  Aimmune Therapeutics to Host Conference Call and Webcast to Discuss Third Quarter 2019 Financial Results and Recent Operational Highlights Business Wire
Oct-28-19 10:59AM  Here is What Hedge Funds Think About Aimmune Therapeutics Inc (AIMT) Insider Monkey
Oct-24-19 04:55PM  Najarian Brothers Highlight Unusual Options Activity In Activision Blizzard, Cronos Group Benzinga
Oct-07-19 06:48AM  My Stock of the Week Is Aimmune Therapeutics TheStreet.com
Oct-03-19 01:24AM  Edited Transcript of AIMT earnings conference call or presentation 8-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
Sep-26-19 07:00AM  Aimmune to Present at the Cantor Global Healthcare Conference Business Wire
Sep-18-19 10:33AM  Biotech Stock Roundup: BIIB Halts AD Study, AMGN Posts Positive MM Drug Data & More Zacks
Sep-16-19 04:19PM  Analyst: DBV's Peanut Allergy Drug Could Outscore Aimmune's On Safety Front Benzinga -5.88%
04:16PM  Profit-Takers Drag This Highflying Biotech Stock Into The Red Investor's Business Daily
01:18PM  Aimmune's Peanut Allergy Drug Gets FDA Committee's Support Zacks
01:15PM  A Look At Benzinga Pro's Most-Searched Tickers For September 16, 2019 Benzinga
Sep-13-19 08:00PM  A Mixed FDA Panel Just Recommended This Biotech's Peanut Allergy Drug Investor's Business Daily
05:53PM  FDA Allergenic Products Advisory Committee Votes to Support the Use of Aimmunes PALFORZIA (AR101) for Peanut Allergy Business Wire
05:10PM  A Mixed FDA Panel Just Recommended This Biotech's Peanut Allergy Drug Investor's Business Daily
04:47PM  First peanut allergy therapy gets backing from U.S. regulators' expert advisers Reuters
10:30AM  Aimmune's stock halted as FDA panel's decision awaited on peanut allergy treatment MarketWatch
07:05AM  Aimmune Stock Trading Halted Today; FDA Allergenic Products Advisory Committee (APAC) Meeting to Discuss PALFORZIA (AR101) for Peanut Allergy Business Wire
06:50AM  Aimmune Stock Halted as FDA Considers Peanut Allergy Treatment TheStreet.com
Sep-11-19 04:18PM  This Biotech Just Hit A 6-Month High; FDA Panel To Consider Allergy Med Investor's Business Daily +15.41%
Sep-10-19 04:37PM  Biotech Stock On The Radar: Aimmune Awaits Adcom Test Benzinga +11.58%
09:40AM  If You're Not Allergic to Risk, Consider Aimmune Therapeutics on Strength TheStreet.com
Sep-09-19 10:23AM  Peanut Allergy Drug Faces Next Test at Key FDA Panel Meeting Bloomberg
09:31AM  3 Biotech Stocks That Could Soar This Week Motley Fool
Sep-05-19 10:12AM  3 Strong Buy Biotech Stocks Ahead of FDA Verdicts SmarterAnalyst +7.67%
Aug-28-19 07:00AM  Aimmune to Participate in Three Investor Conferences in September Business Wire
Aug-26-19 08:54AM  Implied Volatility Surging for Aimmune (AIMT) Stock Options Zacks
Aug-21-19 07:40AM  The Daily Biotech Pulse: Ra Pharma Earns Milestone, Aimmune Doses Patient In Egg Allergy Trial, Cara In-Licenses Platform Benzinga
07:00AM  Aimmune Enrolls First Patient in Phase 2 Trial of AR201 for Egg Allergy Business Wire
Aug-14-19 06:15PM  3 Top Biotech Stocks to Buy in August Motley Fool
Aug-09-19 06:54PM  Aimmune Therapeutics, Inc. (AIMT) Q2 2019 Earnings Call Transcript Motley Fool
Aug-08-19 04:05PM  Aimmune Therapeutics Announces Second Quarter 2019 Financial Results and Provides Operational Highlights Business Wire
09:53AM  DBV Resubmits Regulatory Application For Peanut Allergy Drug, Stock Rallies Benzinga
Aug-06-19 07:00AM  Aimmune to Present at the Wedbush PacGrow Healthcare Conference Business Wire
Jul-12-19 09:47AM  Aimmune Down on Negative ICER Review on Allergy Candidate Zacks
07:24AM  The Daily Biotech Pulse: Hookipa Leaps, Illumina Dims On Q2 Warning, Novartis-Amgen Halt Alzheimer's Study Benzinga
Jul-11-19 06:51PM  Here's Why Aimmune Therapeutics Fell 7% Today Motley Fool -6.94%
08:01AM  Aimmune Statement on Institute for Clinical and Economic Review (ICER) Final Report on AR101 for Peanut Allergy Business Wire
Jul-01-19 03:27PM  Edited Transcript of AIMT earnings conference call or presentation 8-May-19 8:30pm GMT Thomson Reuters StreetEvents
Jun-28-19 07:00AM  Aimmune Submits Marketing Authorization Application to European Medicines Agency for AR101 for Peanut Allergy Business Wire
Jun-25-19 10:18AM  Heres What Hedge Funds Think About Aimmune Therapeutics Inc (AIMT) Insider Monkey
Jun-20-19 09:22AM  Aimmune Therapeutics, Inc. (NASDAQ:AIMT) Is Expected To Breakeven Simply Wall St.
Jun-13-19 09:00AM  What Makes Aimmune Therapeutics (AIMT) a New Buy Stock Zacks
Jun-12-19 08:00AM  Aimmune to Present at the JMP Securities Life Sciences Conference Business Wire
Jun-11-19 08:00AM  Aimmune Therapeutics Discusses AR101s Cost-Effectiveness and Demonstrated Clinical Benefits at ICER Meeting Business Wire
Jun-05-19 08:00AM  Aimmune to Participate in the Goldman Sachs 40th Annual Healthcare Conference Business Wire
Jun-04-19 10:01AM  Data from Two Studies Confirm Quality of Life and Psychosocial Burden of Living with Peanut Allergy Business Wire
07:01AM  New Data from Phase 3 PALISADE Follow-on Study of AR101 for Peanut Allergy Show Continued Immunomodulation Through Daily Dosing Beyond One Year Business Wire
Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy. The company also engages in the research and development of AR201, a CODIT product candidate for the treatment of egg allergy in pediatric and young adult patients; and other CODIT product candidates targeting food allergies, such as cow's milk allergy. Aimmune Therapeutics, Inc. has a strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics; and clinical collaboration agreement with Regeneron Ireland Unlimited Company and Sanofi Biotechnology SAS to study AR101 with adjunctive dupilumab in peanut-allergic patients in a Phase II trial. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ENRIGHT PATRICK GDirectorMar 18Buy11.0616,213179,34570,561Mar 19 05:03 PM
ENRIGHT PATRICK GDirectorMar 17Buy11.40100,0001,139,6506,113,134Mar 19 05:03 PM
ENRIGHT PATRICK GDirectorMar 17Buy11.508,787101,05154,348Mar 19 05:03 PM
Oxtoby AndrewChief Commercial OfficerMar 13Buy14.763,00044,26625,015Mar 17 04:51 PM
BJERKHOLT ERICChief Financial OfficerMar 12Buy15.101,00015,10042,967Mar 12 09:13 PM
Dallas Jayson Donald AlexanderPresident and CEOMar 10Buy18.742,66549,934123,283Mar 10 08:48 PM
BJERKHOLT ERICChief Financial OfficerMar 09Buy18.971,00018,97041,967Mar 10 08:47 PM
Sheehy Douglas T.See RemarksJan 16Option Exercise12.954005,18046,068Jan 21 06:17 PM
Sheehy Douglas T.See RemarksJan 16Sale37.0040014,80045,668Jan 21 06:17 PM
ADELMAN DANIEL C MDChief Medical OfficerJan 02Option Exercise19.6320,000392,60041,250Jan 03 08:41 PM
ADELMAN DANIEL C MDChief Medical OfficerJan 02Sale35.0020,000700,03821,250Jan 03 08:41 PM
Sheehy Douglas T.See RemarksDec 26Option Exercise12.9510,000129,50055,668Dec 30 05:14 PM
Sheehy Douglas T.See RemarksDec 26Sale33.0310,000330,32245,668Dec 30 05:14 PM
ADELMAN DANIEL C MDChief Medical OfficerDec 09Option Exercise11.4520,000229,00041,250Dec 11 05:50 PM
ADELMAN DANIEL C MDChief Medical OfficerDec 09Sale30.0420,000600,71621,250Dec 11 05:50 PM
BJERKHOLT ERICChief Financial OfficerSep 18Buy22.571,55034,97733,574Sep 20 08:55 AM